Plain-English translation of NCT06475209 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two medications—Adebrelimab and Apatinib—can help keep advanced small cell lung cancer under control after initial chemotherapy. The study will involve about 60 patients in China who have already completed their first round of cancer treatment and are doing well. Researchers want to see if this medication combination can help prevent the cancer from coming back and how safe it is to use.
Small cell lung cancer is an aggressive cancer that often comes back even after successful initial treatment. This trial exists to find better ways to keep the cancer from returning for as long as possible, giving patients more time and potentially better quality of life.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or clinic regularly for the next 1–3 years to receive the medications and have your health monitored. Every 3 weeks is one treatment cycle: you would receive one injection of Adebrelimab on day 1, and take Apatinib as a daily pill for 2 weeks, then have 1 week off. During each visit, you would have blood tests, imaging scans, and check-ins with your doctor to make sure the treatment is working and to watch for any side effects. You would continue this treatment as long as the cancer is not growing and you are tolerating the medication well.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China